Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET

European Journal of Cancer

Volumn 46, Issue 13, 2010, Pages 2432-2440

  Hutson, Thomas E ^a   Bellmunt, Joaquim ^b   Porta, Camillo ^c   Szczylik, Cezary ^d   Staehler, Michael ^e   Nadel, Andrea ^f   Anderson, Sibyl ^f   Bukowski, Ronald ^g   Eisen, Tim ^h   Escudier, Bernard ⁱ  

^a TEXAS ONCOLOGY   (United States)

^b HOSPITAL DEL MAR   (Spain)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Bayer HealthCare Pharmaceuticals Inc   (United States)

^g TAUSSIG CANCER INSTITUTE   (United States)

^h Cambridge Biomedical Research Centre   (United Kingdom)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Disease stabilisation; Long term safety; Renal cell carcinoma; Sorafenib; TARGET; Tolerability

Indexed keywords

SORAFENIB;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; COLON HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; EMBOLISM; FATIGUE; FEMALE; FLUSHING; FOLLOW UP; HAND FOOT SYNDROME; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LONG TERM CARE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOSIS; THROMBUS; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; YOUNG ADULT;

EID: 77955917461     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.06.121     Document Type: Article

References (19)

1. R.C. Flanigan, S.E. Salmon, and B.A. Blumenstein Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 2001 1655 1659
2. G.H. Mickisch, A. Garin, P.H. Van, P.L. de, and R. Sylvester Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 2001 966 970
3. J.K. Maranchie, J.R. Vasselli, and J. Riss The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma Cancer Cell 1 2002 247 255
4. R.J. Motzer, B.I. Rini, and R.M. Bukowski Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
5. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
6. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
7. B. Escudier, T. Eisen, and W.M. Stadler Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
8. M.E. Gore, C. Szczylik, and C. Porta Safety and efficacy of sunitinib for metastatic renal-cell carcinoma Lancet Oncol 10 2009 757 763
9. T.E. Hutson, I.D. Davis, and J.H. Machiels Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma J Clin Oncol 28 2010 475 480
10. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
11. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
12. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal cancer Global Evaluation Trial J Clin Oncol 27 2009 3312 3318
13. T.E. Hutson, R.A. Figlin, J.G. Kuhn, and R.J. Motzer Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies Oncologist 13 2008 1084 1096
14. W. Smith, M.S. Kipnes, and T.C. Marbury Effects of renal impairment on the pharmacokinetics and safety of sorafenib Eur J Cancer Suppl 7 2009 433
15. T. Eisen, S. Oudard, and C. Szczylik Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial J Natl Cancer Inst 100 2008 1454 1463
16. M. Schmidinger, C.C. Zielinski, and U.M. Vogl Cardiac toxicity of sunitinib and sorafenib in patients with renal cell carcinoma J Clin Oncol 26 2008 5204 5212
17. R.J. Amato, P. Harris, and M. Dalton A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC) J Clin Oncol 25 18S 2007 5026
18. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
19. B.I. Rini, and M.B. Atkins Resistance to targeted therapy in renal-cell carcinoma Lancet Oncol 10 2009 992 1000